Breast CarcinomaNCT07275203
Concordance of the Biology of Primary Breast Carcinoma and the Biology of Recurrence .
An observational study of Breast Carcinoma, run by Sohag University.
Trial summary
the study will discuss the concordance of the biology of primary breast carcinoma and the biology of recurrence. The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Carcinoma
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2026to 1 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
Who may be able to join
- Age more than18 years old at time of diagnosis of breast cancer.
- Patients who had recurrent breast cancer following adjuvant treatment.
- Biopsy was taken from the site of recurrence and biology was done.
Who cannot join
- Patients with distant metastasis at time of presentation.
- Patients diagnosed with double malignancy.
- Patients with incomplete data records.
- Recurrent breast cancer and biopsy difficult to be taken .
About this study
Official title: Concordance of the Biology of Primary Breast Carcinoma and the Biology of Recurrence , Retrospective Study.
the study will discuss the concordance of the biology of primary breast carcinoma and the biology of recurrence.
The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
including Patients diagnosed and treated between 2015 and 2025 and Data will be collected from medical records, pathology reports, and radiology reports.
- Conditions
- Breast Carcinoma
- Being tested
- No intervention
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
No intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of receptor discordance between primary and recurrent breast cancer.
Measured: 2015-2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2025
- Study start1 Mar 2026 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CarcinomaStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mera Samy George Samy, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07275203
- Sponsor's protocol ID
- Soh-Med--25-11-8MS
- Status last verified
- Nov 2025
- First submitted
- 27 Nov 2025
- Last updated
- 29 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Concordance of the Biology of Primary Breast Carcinoma and the Biology of Recurrence , Retrospective Study.
- ClinicalTrials.gov ID
- NCT07275203
- Acronym / sponsor ID
- Soh-Med--25-11-8MS
- Conditions
- Breast Carcinoma
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Oct 2026 (estimated)
- First posted
- 10 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the study will discuss the concordance of the biology of primary breast carcinoma and the biology of recurrence.
The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
including Patients diagnosed and treated between 2015 and 2025 and Data will be collected from medical records, pathology reports, and radiology reports.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
Key inclusion criteria (3 listed)
- Age more than18 years old at time of diagnosis of breast cancer.
- Patients who had recurrent breast cancer following adjuvant treatment.
- Biopsy was taken from the site of recurrence and biology was done.
Key exclusion criteria (4 listed)
- Patients with distant metastasis at time of presentation.
- Patients diagnosed with double malignancy.
- Patients with incomplete data records.
- Recurrent breast cancer and biopsy difficult to be taken .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionNo intervention | Other | – |
Primary outcome
Rate of receptor discordance between primary and recurrent breast cancer.
Time frame: 2015-2025
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2026.
Related trials for Breast Carcinoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Carcinoma, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of receptor discordance between primary and recurrent breast cancer. (time frame: 2015-2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026.